




# TrichoConcept™

The first line of personalized treatment for alopecia

## Introduction


Alopecia is a chronic dermatological disorder characterized by partial or complete hair loss from one or more body areas, most commonly affecting the scalp (Figure 1).<sup>1</sup> It can be related to systemic conditions, such as autoimmune or endocrine diseases, chronic infections, and nutritional deficiencies.<sup>2</sup>



**Figure 1.** Hair loss: (left) involving the face; (right) involving the scalp.

As important as the chosen active pharmaceutical ingredient (API) or dermaceutical ingredient (DCI), adequate vehicles to apply them on the scalp can contribute positively to achieving treatment efficiency.

Fagron's **TrichoConcept™** is the first global line of multifunctional compounding vehicles with the **TrichoTech™** technology, a patented phytocomplex specially developed for use in personalized alopecia treatment. To achieve the maximum synergistic effect, the ingredients in **TrichoTech™** were selected based on their chemical components and combined in the most adequate concentration to strengthen their therapeutic effects. **TrichoTech™** is present in all **TrichoConcept™** vehicles to provide multiple benefits to the bulb, scalp and shaft (BSS) hair system.<sup>3</sup>



## The Science Behind TrichoTech™

The efficacy of the **TrichoConcept™** line of vehicles and **TrichoTech™** have been validated in both *in vitro* and *in vivo* studies, showing:<sup>2,3</sup>

1. Increase in fibroblasts proliferation
2. Increase in collagen content inside fibroblasts
3. Increase in the expression of fibroblasts growth factors (FGF-7, FGF-10)
4. Stimulation of the anagen phase on hair

**TrichoConcept™** vehicles were developed to be compatible with the majority of the APIs and DCIs used in alopecia treatment, allowing their easy incorporation into the vehicles. There are seven different **TrichoConcept™** vehicles available, each one with exclusive characteristics according to the desired site or application. The vehicles can be grouped into two different categories:



### TrichoSol™

Alcohol-free solution,  
ideal for local  
application



### TrichoFoam™

Foaming vehicle,  
ideal for drip-free  
local application



### TrichoSerum™

Anti-frizz and  
protective vehicle  
for the hair



### TrichoCream™

Gel cream base, ideal  
for small areas application  
(eyelids and eyebrows)



### TrichoOil™

Pre-washing lipid  
vehicle for protection and  
preparation of the hair



### TrichoCond™

Conditioning base,  
to be combined with  
the shampoo



### TrichoWash™

Shampoo base  
ideal for daily use

Combining the use of different vehicles from **TrichoConcept™** ensures adequate scalp preparation to receive the treatment, maintaining the proper surface pH, and hydration and stimulating local blood circulation.





## Patients case studies



Figure 2. Hair shaft images before treatment (baseline), and after 90 days.

### Case Report 1

**Patient identification:** J.P.M.

**Gender:** Male

**Age:** 43

#### Diagnosis

Androgenetic alopecia, seborrheic dermatitis.

#### Treatment protocol

- TrichoOil™ (once per week)
- TrichoWash™ (daily)
- TrichoCond™ (daily)
- TrichoSol™ + Minoxidil 5.0% (daily)

#### Results

After 90 days of treatment with the **TrichoConcept™** protocol, a significant improvement in the desquamation and new hair growth was observed (Figure 2).



Figure 3. Hair shaft images before treatment (baseline), and after 90 days.

### Case Report 2

**Patient identification:** R.S.F.

**Gender:** Male

**Age:** 28

#### Diagnosis

Androgenetic alopecia, seborrheic dermatitis, dry hair.

#### Treatment protocol

- TrichoOil™ (once per week)
- TrichoWash™ + Ciclopirox 1.5% (daily)
- TrichoCond™ + D-panthenol 0.5% + Niacinamide 0.5% (daily)
- TrichoFoam™ + Minoxidil 5.0% (daily)

#### Results

After 90 days of treatment with the **TrichoConcept™** protocol, a significant improvement in the rarefaction and growth of new hair was observed, with complete resolution of scalp discomfort. He also noticed smoother and shinier hair shaft (Figure 3).

## The Safety of TrichoConcept™

All **TrichoConcept™** vehicles were evaluated in clinical studies to assess the skin's primary and accumulated irritation potential, skin sensitization, photoallergy and phototoxicity potential. After the completion of the studies, all the tested products:

- Do not induce primary and accumulated skin irritation
- Do not cause irritation
- Do not induce skin photoallergy or phototoxicity

**TrichoConcept™** is formulated to be biocompatible with the hair and the scalp, without causing dryness or irritation. **TrichoConcept™** is free from allergens and controversial ingredients such as dyes, alcohol, parabens, mineral oils, sodium lauryl sulfate, propylene glycol, phthalates, silicones and petrolatum. **TrichoConcept™** vehicles have no safety concerns associated with any of their components and are cruelty-free, vegan, BSE/TSE-free (Bovine Spongiform Encephalopathy/ Transmissible Spongiform Encephalopathy), and GMO-free.

To maintain the physiology of the BSS hair system and avoid toxicity,  
TrichoConcept™ vehicles are free from controversial ingredients that are frequently used in hair products:



## REFERENCES

1. Phillips, T. G., Slomiany, ; W Paul & Allison, R. *Hair Loss: Common Causes and Treatment*. vol. 96 www.aafp.org/aafp (2017).
2. Jamerson, T. A. & Aguh, C. An Approach to Patients with Alopecia. *Medical Clinics of North America* vol. 105 599–610 Preprint at <https://doi.org/10.1016/j.mcna.2021.04.002> (2021).
3. Polonini, H., Taylor, S. & Zander, C. Compatibility of Different Formulations in TrichoConcept™ Vehicles for Hair Treatments. *Sci Pharm* **90**, (2022).
4. Amaral, F. et al. Effects of the Phytocomplex TrichoTech™ on Human Fibroblasts: Proliferative Potential and Effects on Gene Expression of FGF-7 and FGF-10. *Journal of Cosmetics, Dermatological Sciences and Applications* **07**, 1–13 (2017).
5. Pucci, A. V., Oliveira, A., Amaral, F. & Oliveira, C. R. Effects of Trichosol™ on Increasing the Anagen Phase of the Capillary Cycle of Volunteers. (2019) doi:10.4172/2471-9323.1000139.



## Fagron BV

Fascinatio Boulevard 350  
3065 WB Rotterdam  
The Netherlands

T +31 88 33 11 288  
F +31 88 33 11 210  
[www.fagron.com](http://www.fagron.com)

 **Fagron**  
personalizing  
medicine